The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 3.2M data for 1.4M Compounds and 11.4K Targets. Of those, 1.6M data for 748K Compounds and 4.8K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

To help with training and testing AI and other models, BindingDB downloads and search results now provide the publication date and BindingDB curation date of each measurement.

24 articles for thisTarget


The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Data
Article Title
Organization
Synthesis and anti-influenza evaluation of orally active bicyclic ether derivatives related to zanamivir.EBI
Sankyo
Synthesis and antimycobacterial activity of capuramycin analogues. Part 2: acylated derivatives of capuramycin-related compounds.EBI
Sankyo
Synthesis and anti-influenza virus activity of 7-O-alkylated derivatives related to zanamivir.EBI
Sankyo
Synthesis and anti-influenza virus activity of 4-guanidino-7-substituted Neu5Ac2en derivatives.EBI
Sankyo
Combined NK1 and NK2 tachykinin receptor antagonists: synthesis and structure-activity relationships of novel oxazolidine analogues.EBI
Sankyo
Temocaprilat, a novel angiotensin-converting enzyme inhibitor, is excreted in bile via an ATP-dependent active transporter (cMOAT) that is deficient in Eisai hyperbilirubinemic mutant rats (EHBR).EBI
Sankyo
Synthesis and SAR studies of a novel class of S1P1 receptor antagonists.EBI
Sankyo
4-Aminophenoxyacetic acids as a novel class of reversible cathepsin K inhibitors.EBI
Sankyo
Discovery of novel aldose reductase inhibitors using a protein structure-based approach: 3D-database search followed by design and synthesis.EBI
Sankyo
Structure-activity relationships of phomactin derivatives as platelet activating factor antagonists.EBI
Sankyo
Angiotensin-converting enzyme inhibitors. 2. Perhydroazepin-2-one derivatives.EBI
Sankyo
Novel oximes having 5-benzyl-2,4-thiazolidinedione as antihyperglycemic agents: synthesis and structure-activity relationship.EBI
Sankyo
A novel class of apical sodium-dependent bile acid transporter inhibitors: the amphiphilic 4-oxo-1-phenyl-1,4-dihydroquinoline derivatives.EBI
Sankyo
Synthesis and antimycobacterial activity of capuramycin analogues. Part 1: substitution of the azepan-2-one moiety of capuramycin.EBI
Sankyo
Combined tachykinin receptor antagonist: synthesis and stereochemical structure-activity relationships of novel morpholine analogues.EBI
Sankyo
Aryl C-glycosides: physiologically stable glycomimetics of sialyl Lewis X.EBI
Sankyo
Synthesis and 5 alpha-reductase inhibitory activities of benzofuran derivatives with a carbamoyl group.EBI
Sankyo
Nonpeptide angiotensin II receptor antagonists: synthesis, biological activities, and structure-activity relationships of imidazole-5-carboxylic acids bearing alkyl, alkenyl, and hydroxyalkyl substituents at the 4-position and their related compounds.EBI
Sankyo
Angiotensin-converting enzyme inhibitors: perhydro-1,4-thiazepin-5-one derivatives.EBI
Sankyo
Synthesis and thromboxane synthetase inhibitory activity of di- or tetrahydrobenzo[b]thiophenecarboxylic acid derivatives.EBI
Sankyo
Studies on hindered phenols and analogues. 2. 1,3-Benzoxathioles having SRS-A inhibiting activity.EBI
Sankyo
Substituted imidazo[1,2-B]pyridazines as protein kinase inhibitorsBDB
Tolero Pharmaceuticals
Imidazolone derivatives, pharmaceutical compositions and uses thereofBDB
Beijing Forelandpharma
Histone deacetylase inhibitors and compositions and methods of use thereofBDB
Chdi Foundation